ArticleInternational urology and nephrology2019
Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2023Pooled it
- Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.Clinical rheumatology · 2020Pooled it
- Renoprotective effect of febuxostat on contrast-induced acute kidney injury in chronic kidney disease patients stage 3: randomized controlled trial.BMC nephrology · 2023Trial
- Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria.Pediatric nephrology (Berlin, Germany) · 2021Trial
- Effectiveness of Allopurinol on Uric Acid and Pediatric Chronic Kidney Disease Severity in the Chronic Kidney Disease in Children Study.Kidney medicine · 2025Article
- Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease.Medical science monitor : international medical journal of experimental and clinical research · 2024Observational
- Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment.International journal of molecular sciences · 2022Review
- The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia.Journal of healthcare engineering · 2022Article
- Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia.Emergency medicine international · 2022Article
- Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.PloS one · 2022Article
- Hyperuricemia, the heart, and the kidneys - to treat or not to treat?Renal failure · 2020Review
- Renal effects of uric acid: hyperuricemia and hypouricemia.The Korean journal of internal medicine · 2020Review
- Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients.Renal failure · 2020Article
- Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection.Current hypertension reports · 2020Review
- Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.International urology and nephrology · 2019Article
- Serum uric acid is an independent predictor of renal outcomes in patients with idiopathic membranous nephropathy.International urology and nephrology · 2019Article
- Hyperuricemia and chronic kidney disease: to treat or not to treat.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to compare the renoprotective effect between febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease (CKD), about which limited data are available.
methods141 patients with stage 3 CKD and hyperuricemia were followed from June 2005 to April 2018. Thirty patients received febuxostat, 40 allopurinol and 71 conventional CKD management only (control group). We compared the mean serum uric acid levels, estimated glomerular filtration rate (eGFR) changes over time and renal survival time free from predefined renal disease progression among these 3 groups.
resultsOverall, mean age was 62.6 ± 13.3 years, baseline eGFR 42.1 ± 8.8 mL/min/1.73 m
conclusionsFebuxostat seems to reduce serum uric acid level and to retard renal disease progression more effectively than allopurinol in hyperuricemic patients with CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.